Risperidone-induced Hyperprolactinemia Research Articles

Ziprasidone Substitution in a Patient with Risperidone-Induced Hyperprolactinemia

Ziprasidone Substitution in a Patient with Risperidone-Induced Hyperprolactinemia

Panhypogammaglobulinemia Associated with Phenytoin Therapy;Status Epilepticus after Abrupt Withdrawal of High-Dose Gabapentin Therapy;Thalidomide-Induced Neuropathy;Ergot Toxicity as a Result of Over-the-Counter Drug Use;Systemic Absorption of Ophthalmic Medication Leads to Child's Overdose;Risperidone-Induced Hyperprolactinemia

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

Resolution of Risperidone-Induced Hyperprolactinemia with Substitution of Quetiapine

Resolution of Risperidone-Induced Hyperprolactinemia with Substitution of Quetiapine

Resolution of Risperidone-Induced Hyperprolactinemia with Substitution of Quetiapine

Resolution of Risperidone-Induced Hyperprolactinemia with Substitution of Quetiapine

Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.

Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children. Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature. These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth. We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth. We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline. Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week). When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects. The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days. Cabergoline was well tolerated without adverse effects. Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.